hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang上一页:自身免疫病也可以免疫治疗
下一页:癫痫发作的症状是什么?
- 2022-05-10“T+A”方案显著改善中叶肝癌患者总生存期,邢宝才教授解读IMbre150最新结果丨ASCO GI
- 2022-05-05广州省综合医院|小儿癫痫病人的早期症状有哪些
- 2022-05-03Lancet:偏头痛看过来!柳叶刀最新文章揭示:瑞美吉泮可安全有利于预防偏头痛
- 2022-04-28癫痫的放射治疗 放射治疗癫痫的偏方大全(2)
- 2022-04-12诺华银屑病药物 Secukinumab 比依那西普好
- 2022-04-11焦虑和疾病认知影响银屑病关节炎患者的健康生活量表
- 诺华银屑病药物 Secukinumab 比依那西普好
- 焦虑和疾病认知影响银屑病关节炎患者的健康生活量表
- 低剂量阿司匹林可预防结直肠癌
- 月经性癫痫患者妊娠期癫痫控制更好
- 综述:癫痫持续状态诊治最新进展
- 预测癫痫患者再入院风险
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 预防应该做哪些准备?
- 由于医生的原因,物「沉默」而且很难进入处方
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 皮肤过敏症状 皮肤过敏通常表现出五种症状
- 三庚酸酯可治疗1型转运体缺陷综合征
- 心理百科:春节期间小心疾病
- spa中国有五个专业spa会所介绍
- Clin Gastroenterology?H:?多潘立酮治疗对胃轻瘫症状的影响
- 癫痫发作的症状是什么?
- 2013国际抗癫痫联合会抗癫痫药用指南
- 自身免疫病也可以免疫治疗
- 智能手机真能成为诊断工具吗?未必!
- 中医如何治疗癫痫 癫痫预防?
- FDA 批准银屑病新药 ixekizumab
- 输卵管有话要说,耐心看完这些话
- 手足口病的初始症状 手足口病的表现是什么?
- 虽然医学越来越发达,但这四种疾病尚未治愈!别再上当了
- 通过尿色自测健康状况(7)
- 最佳癫痫病治疗方法腹泻是什么
- 小儿癫痫病有什么腹泻
- 癫痫病的常见病因都有什么
- “药不能停”!擅自停药,中风频繁发作
- 癫痫病的发作有哪些病征
- [推荐收藏]癫痫急救应将及常见误区~!
- 怎样病人癫痫病病人方法
- 治疗男士癫痫病的多钱
- 癫痫病有哪些哮喘-
- 丘脑前核电刺激(ANT-DBS)病患药物难治性癫痫
- 导致癫痫病发病原因
- 怎么放射治疗癫痫病xgrb
- 无可治性癫痫“无可”在哪里?治疗如何少走弯路!
- 外科手术癫痫病最佳
- 青少年癫痫病要怎么防治